Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LM-108 plus toripalimab in MSI-H/dMMR advanced solid tumors after prior PD-1/PD-L1 failure
CTR20250219Phase 2Active
- Sponsor
- LaNova Medicines
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LM-108, toripalimab in Nonhematologic neoplasms, microsatellite instability-high cancer, mismatch repair deficient solid tumor, sponsored by LaNova Medicines. Started Mar 2025; status: active.
02
Drugs
LM-108toripalimab
03
Conditions
Nonhematologic neoplasmsmicrosatellite instability-high cancermismatch repair deficient solid tumor
Beyond the preview
Go deeper on CTR20250219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250219.